Insulet Corporation (PODD)
NasdaqGS · USD · Healthcare · Medical Devices
$149.83 (+0.38%) as of
Key statistics
- Market cap
- 10.39B
- P/E (TTM)
- 28.06
- Forward P/E
- 19.40
- EPS (TTM)
- 5.34
- Dividend yield
- 0.00%
- 52-week range
- 126.40 – 354.88
- Beta
- 1.10
- Revenue (TTM)
- 3.05B
- Profit margin
- 12.29%
- Analyst target
- $167.17
- Volume
- 943.68k
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Acton, MA, United States
- Employees
- 5,400
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.